SuperworthContext Therapeutics EPS CNTX
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.48
- Latest quarter, Q2 FY26
- −$0.15
- Fiscal year 2025
- −$0.38
Context Therapeutics' earnings per share was −$0.48 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.15.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.38 | n/a |
| FY2024 | −$0.53 | n/a |
| FY2023 | −$1.50 | n/a |
| FY2022 | −$0.93 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.15 | n/a | −$0.48 | |
| Q1 FY26 | −$0.09 | n/a | −$0.42 | |
| Q4 FY25 | −$0.14 | n/a | −$0.38 | |
| Q3 FY25 | −$0.10 | n/a | −$0.28 | |
| Q2 FY25 | −$0.09 | n/a | −$0.40 | |
| Q1 FY25 | −$0.05 | n/a | −$0.35 | |
| Q4 FY24 | −$0.04 | n/a | −$0.53 | |
| Q3 FY24 | −$0.22 | n/a | −$0.91 | |
| Q2 FY24 | −$0.04 | n/a | −$1.06 | |
| Q1 FY24 | −$0.23 | n/a | −$1.33 | |
| Q4 FY23 | −$0.42 | n/a | −$1.50 | |
| Q3 FY23 | −$0.37 | n/a | −$1.30 |
Against its peers
Companies in Drug Manufacturers - General nearest Context Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CNTXContext Therapeutics | −$0.48 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Context Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.